吡非尼酮治療特發性肺纖維化: 我們擁有多少證據?_《中國呼吸與危重監護雜志》

作者：

孫淵蔡后榮 ¹

1 南京中醫藥大學中西醫結合鼓樓臨床學院( 江蘇南京 210029) ;;
2 南京大學醫學院附屬鼓樓醫院呼吸科( 江蘇南京 210008);

關鍵詞：

吡非尼酮特發性肺纖維化

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

特發性肺纖維化( idiopathic pulmonary fibrosis, IPF) 為原因不明, 局限于肺, 以普通型間質性肺炎( usual interstitialpneumonitis, UIP) 為病理特征的慢性進行性發展的纖維化性間質性肺疾病。該病預后不良, 現無有效治療藥物[1] , 尋找有效治療IPF的藥物始終是該研究領域的熱點之一。迄今已有諸多針對肺纖維化發病機制的基礎研究成果, 并陸續轉化為新的研究藥物[2] 。IPF 臨床中心協作網的建立使數以百計的IPF患者比較快地入組參加新藥物臨床試驗, 并順利完成了多項高質量的雙盲、隨機、安慰劑對照臨床試驗, 有力推動了IPF 治療領域的進展。遺憾的是, 近幾年已發表的多項臨床試驗結果[3-6] 令人失望。在挫折和期盼之中, 最新發表的吡非尼酮( pirfenidone) 治療IPF臨床試驗結果[7] 為無藥可治的IPF患者帶來了一線希望的曙光。

引用本文： 孫淵蔡后榮. 吡非尼酮治療特發性肺纖維化: 我們擁有多少證據?. 中國呼吸與危重監護雜志, 2010, 9(5): 456-457. doi: 復制

1.	American Thoracic Society/ European Respiratory Society. American Thoracic Society /European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med, 2002, 165 : 277-304 .
2.	du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov, 2010 , 9: 129-140 .
3.	Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med, 2010, 181 : 604-610.
4.	King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis ( INSPIRE) : a multicentre, randomised, placebo-controlled trial.Lancet, 2009, 374 : 222-228.
5.	King TE Jr, Behr J, Brown KK, et al. BUILD-1 : a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med, 2008, 177: 75-81.
6.	Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial. Am J Respir Crit Care Med, 2008, 178: 948 -955.
7.	Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2010, 35: 821-829.
8.	Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med, 1999, 159: 1061-1069.
9.	Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2005, 171: 1040 -1047 .
10.	Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J, 2010, 35 : 728-729.
11.	King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1 b for idiopathic pulmonary fibrosis. Chest, 2005, 127: 171 -177.
12.	Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat, 2002,12:207-226.
13.	Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimumimportant differences in IPF. Respir Med,2010, 104: 296-304.
14.	InterMune. Investor Relations. Available from: http: / /phx.corporate-ir. net/ phoenix. zhtml? c = 100067&p = irol-IRHome .Date last accessed:May 17, 2010 .

1. American Thoracic Society/ European Respiratory Society. American Thoracic Society /European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med, 2002, 165 : 277-304 .
2. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov, 2010 , 9: 129-140 .
3. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med, 2010, 181 : 604-610.
4. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis ( INSPIRE) : a multicentre, randomised, placebo-controlled trial.Lancet, 2009, 374 : 222-228.
5. King TE Jr, Behr J, Brown KK, et al. BUILD-1 : a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med, 2008, 177: 75-81.
6. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebocontrolled trial. Am J Respir Crit Care Med, 2008, 178: 948 -955.
7. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2010, 35: 821-829.
8. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med, 1999, 159: 1061-1069.
9. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2005, 171: 1040 -1047 .
10. Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J, 2010, 35 : 728-729.
11. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1 b for idiopathic pulmonary fibrosis. Chest, 2005, 127: 171 -177.
12. Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat, 2002,12:207-226.
13. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimumimportant differences in IPF. Respir Med,2010, 104: 296-304.
14. InterMune. Investor Relations. Available from: http: / /phx.corporate-ir. net/ phoenix. zhtml? c = 100067&p = irol-IRHome .Date last accessed:May 17, 2010 .

《中國呼吸與危重監護雜志》

吡非尼酮治療特發性肺纖維化: 我們擁有多少證據?

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國呼吸與危重監護雜志》

吡非尼酮治療特發性肺纖維化: 我們擁有多少證據?

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料